PADI4 and neoplasm: In PDAC models, PAD4 inhibition (e.g., GSK484) reduces NET formation and curtails tumor growth [113,223,224], while PAD4 deletion or treatment with JBI-589 impairs metastasis and markedly improves responses to immune checkpoint blockade [113,225].